TLN 254
Alternative Names: TLN-254Latest Information Update: 15 Jan 2025
Price :
$50 *
At a glance
- Originator Treeline Biosciences
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I T-cell lymphoma
Most Recent Events
- 16 Dec 2024 Phase-I clinical trials in T-cell lymphoma (Second-line therapy or greater) in USA (PO) (NCT06733441)
- 13 Dec 2024 Preclinical trials in T-cell lymphoma in USA (PO)
- 13 Dec 2024 Treeline Biosciences plans a phase-I trial for T-cell lymphoma (Second-line therapy or greater) in USA (PO), (NCT06733441)